China's first umbilical cord mesenchymal stem cells to treat heart failure into clinical research stage
Release date: 2017-02-20
Heart failure, referred to as heart failure, is a clinical syndrome of various heart disease developments to the end stage, and is also the "number one killer" of cardiovascular disease. According to data released by the International Summit Forum on Stem Cell Therapy for Ischemic Heart Failure, the number of patients with heart failure worldwide is about 117 million, of which the number of heart failure patients in China is 29.971 million, accounting for 25.6% of the total number of heart failure patients worldwide.
"The five-year mortality rate of heart failure patients is comparable to the number of malignant tumors. If you can pay attention to heart failure patients as early as possible, his five-year and ten-year survival rates may be better than those of malignant tumors. The treatment of heart failure is often When the patient is sick, he goes to the hospital and adjusts to go back, but it will happen again after a while." Professor Liu Zhongmin, dean of Shanghai Oriental Hospital, doctoral tutor.
With the gradual improvement of stem cell isolation, culture, and amplification techniques, as well as the continuous improvement of interventions for heart failure patients, the use of stem cell technology to treat heart failure has now dawned. In December 2016, the officially documented stem cell clinical research project announced by the National Health and Family Planning Commission, Shanghai Oriental Hospital’s “Clinical Study of Human Umbilical Cord Mesenchymal Stem Cell Therapy for Heart Failure†passed the record, which means that the national level faces this. A clinical study is recognized.
Neonatal umbilical cord tissue is rich in mesenchymal stem cells, which are umbilical cord mesenchymal stem cells. It is a pluripotent stem cell with high differentiation potential, can differentiate in multiple directions, and has broad clinical applications in tissue engineering such as bone, cartilage, muscle, tendon, ligament, nerve, liver, endothelium and myocardium. prospect.
So far, there have been more than 100 studies on the treatment of heart failure in stem cells in the international arena. The clinical research on the treatment of heart failure by umbilical cord mesenchymal stem cells has made significant progress. The most concerned is a study by the United States and the European Union. The extracted mesenchymal stem cells are differentiated into myocardial precursor cells by using a unique patented cell recombination technique in vitro, and implanted into the damaged heart site of the patient through a cardiac catheter to realize myocardial cell regeneration, thereby treating ischemic heart. Depletion. The study has now been approved for Phase III clinical trials, and it is not ruled out that it will be officially available in the next few years.
The clinical study of umbilical cord mesenchymal stem cells prepared by Shanghai Oriental Hospital for the treatment of heart failure is the first study of the effect of umbilical cord mesenchymal stem cells on heart failure in China. In this study, the hospital will recruit 10 under 70 years of age. In patients with ischemic heart disease, coronary artery bypass grafting was performed under general anesthesia, and umbilical cord mesenchymal stem cells were injected into the edge of myocardial infarction at 20 points. After discharge, patients were regularly followed to observe the umbilical cord. Mesenchymal stem cells evaluate the safety and efficacy of treatment methods for patients with symptom improvement, improvement of cardiac function and myocardial remodeling.
According to Professor Liu Zhongmin, the application of stem cells in the treatment of heart failure includes cell technology and the minimally invasive catheter technology that can be used to determine the outcome of heart failure at any time and place, reducing patient economic expenditure and improving life. quality.
"Cell technology is more reproducible, and it is convenient to inject with a catheter. This technology can not only treat patients with heart failure, but also diabetes, osteoarthrosis, senile dementia, Parkinson's disease, body damage, liver failure. Renal failure, even including defective organs, such as ear reconstruction, tracheal reconstruction, etc., can not bring the role of traditional medicine to patients." Liu Zhongmin said.
Source: Sichuan Online
Ningbo Staneex Imp. & Exp. Co., Ltd. , https://www.staneex.com